Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 110 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,489,000 | -4.7% | 172,584 | 0.0% | 0.02% | -18.2% |
| Q2 2022 | $2,611,000 | +27.4% | 172,584 | 0.0% | 0.02% | +57.1% |
| Q1 2022 | $2,050,000 | -31.1% | 172,584 | -6.0% | 0.01% | -26.3% |
| Q4 2021 | $2,977,000 | -41.5% | 183,692 | +3.1% | 0.02% | -45.7% |
| Q3 2021 | $5,085,000 | -45.1% | 178,181 | -1.7% | 0.04% | -44.4% |
| Q2 2021 | $9,264,000 | +8.3% | 181,181 | +0.7% | 0.06% | -11.3% |
| Q1 2021 | $8,557,000 | -4.0% | 179,945 | -0.0% | 0.07% | 0.0% |
| Q4 2020 | $8,910,000 | +27.0% | 179,946 | -1.5% | 0.07% | +7.6% |
| Q3 2020 | $7,014,000 | -1.6% | 182,704 | +10.7% | 0.07% | -12.0% |
| Q2 2020 | $7,128,000 | +305.5% | 164,997 | +186.7% | 0.08% | +294.7% |
| Q1 2020 | $1,758,000 | -2.2% | 57,546 | +0.0% | 0.02% | 0.0% |
| Q4 2019 | $1,798,000 | – | 57,526 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |